[{"id":"4aeea117-34ac-4801-a9a7-3c04faeab1e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05912244","created_at":"2023-06-22T20:09:31.362Z","updated_at":"2025-02-25T16:18:54.885Z","phase":"Phase 2","brief_title":"A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma","source_id_and_acronym":"NCT05912244","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cylembio (imsapepimut and etimupepimut, adjuvanted) • Opdualag (nivolumab/relatlimab-rmbw)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/09/2023","start_date":" 06/09/2023","primary_txt":" Primary completion: 06/09/2027","primary_completion_date":" 06/09/2027","study_txt":" Completion: 06/09/2027","study_completion_date":" 06/09/2027","last_update_posted":"2024-08-16"},{"id":"9d1d5f8f-7b04-49f6-9e8a-92b8e7a77fa3","acronym":"KEYNOTE-D38","url":"https://clinicaltrials.gov/study/NCT05077709","created_at":"2021-10-14T19:57:33.332Z","updated_at":"2025-02-25T16:16:45.691Z","phase":"Phase 2","brief_title":"IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC","source_id_and_acronym":"NCT05077709 - KEYNOTE-D38","lead_sponsor":"IO Biotech","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cylembio (imsapepimut and etimupepimut, adjuvanted) • IO103"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 02/14/2022","start_date":" 02/14/2022","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-07-23"},{"id":"5c9805aa-f9a6-41fd-96e7-7f8d0f28c893","acronym":"","url":"https://clinicaltrials.gov/study/NCT05533697","created_at":"2022-09-09T15:55:01.162Z","updated_at":"2024-07-02T16:35:07.372Z","phase":"Phase 1/2","brief_title":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05533697","lead_sponsor":"ModernaTX, Inc.","biomarkers":" EGFR • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • mRNA-4359"],"overall_status":"Recruiting","enrollment":" Enrollment 194","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 12/08/2027","primary_completion_date":" 12/08/2027","study_txt":" Completion: 12/08/2027","study_completion_date":" 12/08/2027","last_update_posted":"2024-04-26"},{"id":"96e48296-f381-4772-98f3-07a1e8a41503","acronym":"KEYNOTE-E40","url":"https://clinicaltrials.gov/study/NCT05280314","created_at":"2022-03-15T18:52:56.379Z","updated_at":"2025-02-25T16:17:24.858Z","phase":"Phase 2","brief_title":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors","source_id_and_acronym":"NCT05280314 - KEYNOTE-E40","lead_sponsor":"IO Biotech","biomarkers":" CD4","pipe":" | ","alterations":" CDKN2A negative","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cylembio (imsapepimut and etimupepimut, adjuvanted)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/21/2023","start_date":" 12/21/2023","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-03-18"},{"id":"6c84103e-94f8-45d1-b084-4f1170d64d4f","acronym":"KEYNOTE-D18","url":"https://clinicaltrials.gov/study/NCT05155254","created_at":"2021-12-13T14:12:44.051Z","updated_at":"2025-02-25T16:17:02.361Z","phase":"Phase 3","brief_title":"IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)","source_id_and_acronym":"NCT05155254 - KEYNOTE-D18","lead_sponsor":"IO Biotech","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cylembio (imsapepimut and etimupepimut, adjuvanted) • IO103"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 407","initiation":"Initiation: 05/17/2022","start_date":" 05/17/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-01-09"},{"id":"2f7de6f9-5668-4b83-820d-b62ff50be145","acronym":"","url":"https://clinicaltrials.gov/study/NCT04445064","created_at":"2021-06-23T19:54:36.637Z","updated_at":"2025-02-25T16:15:55.863Z","phase":"Phase 2","brief_title":"Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.","source_id_and_acronym":"NCT04445064","lead_sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cylembio (imsapepimut and etimupepimut, adjuvanted) • IO102"],"overall_status":"Recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 08/14/2020","start_date":" 08/14/2020","primary_txt":" Primary completion: 06/08/2024","primary_completion_date":" 06/08/2024","study_txt":" Completion: 06/08/2024","study_completion_date":" 06/08/2024","last_update_posted":"2022-05-12"},{"id":"7f63c016-67db-4616-848e-c7533e0a9c03","acronym":"","url":"https://clinicaltrials.gov/study/NCT01792050","created_at":"2021-01-17T17:37:30.462Z","updated_at":"2024-07-02T16:36:44.699Z","phase":"Phase 2","brief_title":"Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer","source_id_and_acronym":"NCT01792050","lead_sponsor":"NewLink Genetics Corporation","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • indoximod (NLG8189)"],"overall_status":"Completed","enrollment":" Enrollment 169","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 07/07/2017","study_completion_date":" 07/07/2017","last_update_posted":"2020-05-28"},{"id":"dd33b34c-fa94-48d0-9b99-6201650c2301","acronym":"","url":"https://clinicaltrials.gov/study/NCT01560923","created_at":"2021-01-18T06:36:45.368Z","updated_at":"2024-07-02T16:36:46.704Z","phase":"Phase 2","brief_title":"Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer","source_id_and_acronym":"NCT01560923","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e indoximod (NLG8189) • Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 12/12/2018","primary_completion_date":" 12/12/2018","study_txt":" Completion: 12/12/2018","study_completion_date":" 12/12/2018","last_update_posted":"2020-04-03"}]